Tema Heart & Health ETF (NASDAQ:HRTS) Short Interest Update

Tema Heart & Health ETF (NASDAQ:HRTS) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,158 shares, an increase of 105.7% from the August 15th total of 2,508 shares. Based on an average daily volume of 2,948 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.3% of the shares of the stock are short sold.

Hedge Funds Weigh In On Tema Heart & Health ETF

A number of institutional investors and hedge funds have recently bought and sold shares of HRTS. Kestra Advisory Services LLC purchased a new stake in Tema Heart & Health ETF during the 4th quarter valued at about $27,000. JPMorgan Chase & Co. acquired a new position in shares of Tema Heart & Health ETF during the 2nd quarter worth approximately $63,000. Citadel Advisors LLC acquired a new stake in shares of Tema Heart & Health ETF in the third quarter valued at approximately $243,000. XML Financial LLC acquired a new stake in shares of Tema Heart & Health ETF in the second quarter valued at approximately $223,000. Finally, Anson Capital Inc. purchased a new position in Tema Heart & Health ETF during the second quarter worth approximately $297,000.

Tema Heart & Health ETF Trading Up 1.4%

HRTS stock traded up $0.51 during midday trading on Monday, reaching $36.54. The stock had a trading volume of 207 shares, compared to its average volume of 5,782. Tema Heart & Health ETF has a 52-week low of $29.54 and a 52-week high of $38.87. The company’s fifty day simple moving average is $37.13 and its 200 day simple moving average is $35.24. The company has a market cap of $54.44 million, a price-to-earnings ratio of 22.06 and a beta of 0.63.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.